Clinical Relevance of Cytochrome P450 Pharmacogenetics

这个应用程序提供了一个以患者为中心的研究计划，旨在支持指导和 由David Flockhart医学博士进行的研究计划。申请者是GCRC调查员，他有 在HIS资助和出版的、以病人为中心的调查和指导方面有良好的记录 指定研究方向：临床药物遗传学。他已经达到了快速和富有成效的阶段。 在他的职业生涯中，沉重的临床和管理责任可能会破坏他的 生产力。这一奖项应该会让他继续专注于以患者为导向的研究领域 细胞色素P450药物遗传学和初级临床研究人员的指导。候选人将会 继续并扩大细胞色素P450广泛领域的多学科研究计划 药物遗传学，重点研究两种已知具有明显功能多态性的酶：CYP2D6 和CYP3A5，还有一种需要更多研究的：CYP2B6。指导机会将来自 正在进行的乳腺癌治疗的药物遗传学研究，包括旨在 验证细胞色素P450药物遗传学可用于预测 他莫昔芬，以及芳香酶抑制剂、艾滋病毒、镰刀细胞病和 申请人在其中扮演积极指导角色的儿科肿瘤学。Flockhart博士是该中心的主任 印第安纳大学临床药理学分部T-32临床药理学培训助学金 以及药物基因组学、伦理学和公共政策研究基金的联合主任。因此，他是高度_ 有资格在临床药物基因组学领域提供临床研究培训，并指导杨 临床调查员。印第安纳大学医学院对病人来说是一个出色的环境- 面向研究，具有强大的GCRC、强大的信息学基础设施和充满活力的 生物伦理学，所有这些都是承诺的，对候选人的制度支持。

This application presents a program of patient-oriented research designed to support a mentoring and research plan carried out by David Flockhart MD, PhD. The applicant is a GCRC investigator, who has a substantial track record in funded and published, patient-oriented investigation and mentoring in his designated area of study: Clinical Pharmacogenetics. He has reached a stage of rapid and productive growth in his career, at which heavy clinical and administrative responsibilities threaten to undermine his productivity. This award should allow him to continue to focus on patient-oriented research in the area of cytochrome P450 pharmacogenetics and on the mentoring of junior clinical investigators. The candidate will continue and expand a multidisciplinary research program in the broad area of cytochrome P450 pharmacogenetics, focusing on two enzymes known to possess clear functional polymorphisms: CYP2D6 and CYP3A5, and one where more research is necessary: CYP2B6. Mentoring opportunities will derive from ongoing studies on the pharmacogenetics of the treatment of breast cancer, including studies designed to test the hypothesis that cytochrome P450 pharmacogenetics can be used to anticipate the effects of tamoxifen, as well as from studies in the areas of Aromatase inhibitors, HIV, Sickle Cell disease and Pediatric Oncology in which the applicant plays an active mentoring role. Dr. Flockhart is Director of the Division of Clinical Pharmacology at Indiana University, P.I. of a T-32 Clinical Pharmacology Training Grant and co-director of a fellowship in Pharmacogenomics, Ethics and Public Policy. As such, he is highly _ qualified to provide clinical research training in the area of clinical pharmacogenomics, and to mentor young clinical investigators. The Indiana University School of Medicine is an outstanding environment for patient- oriented research with a strong GCRC, a strong informatics infrastructure and a vigorous Center for Bioethics, all of which are committed, institutional supports for the candidate.